# Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer

> **NCT07656038** · PHASE1 · NOT_YET_RECRUITING · sponsor: **STCube, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Colonrectal Cancer (CRC)

## Interventions

- **DRUG:** Nelmastobart in combination with TAS-102 and Bevacizumab

## Key facts

- **NCT ID:** NCT07656038
- **Lead sponsor:** STCube, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07656038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07656038, "Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07656038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*